Indigenous babies that are disproportionately impacted with RSV.

Currently the Canadian government is reviewing the licensing of the single dose RSV antibody Nirsevimab (Beyfortus) for the prevention of RSV hospitalizations in infants.

It has already been approved in Europe. 

We want to make sure that Indigenous babies in the rural and remote communities of Canada are eligible for NIrsevizmab to reduce the impact of RSV hospitalizations.

With almost a quarter of a million signatures: WE HAVE A VOICE. LET’S BE HEARD

Tweet and email key decision makers!

Sample message: Ensure Indigenous babies in the rural and remote communities of Canada are protected from RSV. License the single dose antibody Nirsevimab (Beyfortus) to prevent RSV hospitalizations in infants. #RSVremote @SuzanneMcgurn @jyduclos @PattyHajdu change.org/FairMedicine 

Email: 

• Suzanne McGurn, Chief Executive Officer and President - smcgurn@cadth.ca
• Jean-Yves Duclos, Minister of Health - jean-yves.duclos@parl.gc.ca
• Patty Hajdu, Minister of Indigenous Services - patty.hajdu@parl.gc.ca 

We are on the home stretch to victory!